Earnings ·
Rani Therapeutics Holdings reported second quarter 2026 financial results, posting a net loss of $8.4 million compared…
RANIRani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings reported second quarter 2026 financial results, posting a net loss of $8.4 million compared to $11.2 million in the prior year period. Cash and marketable securities totaled $53.4 million as of June 30, 2026, up from $43.4 million at March 31, 2026. The company completed a $20 million registered direct offering in May 2026 to strengthen its cash position. Clinically, Rani dosed the first participants in the Phase 1a expansion cohort of RT-114 and announced positive initial data showing oral bioavailability exceeding matched subcutaneous dosing by over 150%. The company also entered a research collaboration with PegBio for obesity pipeline candidates and appointed Nicholas Maestas as CFO and Michelle Gilson to its Board. Rani Therapeutics is a clinical-stage biotechnology company focused on developing the RaniPill oral delivery platform for biologics.